Journal
EMBO JOURNAL
Volume 31, Issue 19, Pages 3856-3870Publisher
WILEY
DOI: 10.1038/emboj.2012.241
Keywords
A20; deubiquitinase; lymphoma; NF-kappa B; ubiquitin
Categories
Funding
- Japan Society for the Promotion of Science (JSPS)
- Core Research for Evolutional Science and Technology (CREST) Program of Japan Science and Technology Agency (JST)
- Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- Uehara Memorial Foundation
- Grants-in-Aid for Scientific Research [24112001, 23687014, 22687007, 23700517, 23591263, 22117007] Funding Source: KAKEN
Ask authors/readers for more resources
LUBAC (linear ubiquitin chain assembly complex) activates the canonical NF-kappa B pathway through linear polyubiquitination of NEMO (NF-kappa B essential modulator, also known as IKK gamma) and RIP1. However, the regulatory mechanism of LUBAC-mediated NF-kappa B activation remains elusive. Here, we show that A20 suppresses LUBAC-mediated NF-kappa B activation by binding linear polyubiquitin via the C-terminal seventh zinc finger (ZF7), whereas CYLD suppresses it through deubiquitinase (DUB) activity. We determined the crystal structures of A20 ZF7 in complex with linear diubiquitin at 1.70-1.98 angstrom resolutions. The crystal structures revealed that A20 ZF7 simultaneously recognizes the Met1-linked proximal and distal ubiquitins, and that genetic mutations associated with B cell lymphomas map to the ubiquitin-binding sites. Our functional analysis indicated that the binding of A20 ZF7 to linear polyubiquitin contributes to the recruitment of A20 into a TNF receptor (TNFR) signalling complex containing LUBAC and I kappa B kinase (IKK), which results in NF-kappa B suppression. These findings provide new insight into the regulation of immune and inflammatory responses. The EMBO Journal (2012) 31, 3856-3870. doi:10.1038/emboj.2012.241; Published online 28 August 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available